Notably, a recent study has demonstrated that the anti-hypertensive drug syrosingopine is a dual MCT1 and MCT4 inhibitor and that it elicited synthetic lethality when used with metformin, an inhibitor of complex I activity, to treat human cancer cells30. Here, SLC16A3 is linked to cancer.